{
  "abstract": "We read with great interest the study by Lai, Yang, Lee et al, which used a large multicentre cohort to establish non-invasive test thresholds—Fibrosis-4 Index (FIB-4) ≥325 or liver stiffness measurement (LSM) ≥20 kPa (or LSM ≥15 kPa in the two-step algorithm)—to guide hepatocellular carcinoma (HCC) surveillance in patients with metabolic dysfunction-associated steatotic liver disease (MASLD).",
  "authors": [
    {
      "affiliations": [
        "The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China"
      ],
      "name": "Wei Gao"
    },
    {
      "affiliations": [
        "The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China"
      ],
      "name": "Chen Liu"
    }
  ],
  "title": "Letter to the editor regarding: Lai, Jimmy Che-To, et al \"Non-invasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease\"",
  "uid": "ef7c095e-d8e9-591f-b905-8f2b15eb1498"
}